Comparative Efficacy of Immunosuppressive Therapies in the Treatment of Diffuse Cutaneous Systemic Sclerosis
Taken together, our findings robustly support routine use of MMF in dcSSc and show benefit especially in early-stage disease. Those patients with high-risk antibodies for lung fibrosis might be especially suitable for MMF treatment.
Authors
- Robert Spiera (ORCID: https://orcid.org/0000-0003-2911-6800)
- Laura K. Hummers (ORCID: https://orcid.org/0000-0002-4864-4011)
- Eun Bong Lee (ORCID: https://orcid.org/0000-0003-0703-1208)
- Suzanne Kafaja
- Wendy Stevens
- Daniel E. Furst (ORCID: https://orcid.org/0000-0001-7857-2373)
- Oliver Distler (ORCID: https://orcid.org/0000-0002-0546-8310)
- Barbara White (ORCID: https://orcid.org/0000-0003-4679-665X)
- Tracy Frech (ORCID: https://orcid.org/0000-0002-5472-3840)
- Dinesh Khanna (ORCID: https://orcid.org/0000-0003-1412-4453)
- Masataka Kuwana (ORCID: https://orcid.org/0000-0001-8352-6136)
- Christopher P. Denton (ORCID: https://orcid.org/0000-0003-3975-8938)
Institutions
- Hospital for Special Surgery (US)
- Seoul National University (KR)
- Johns Hopkins University (US)
- University of California, Los Angeles (US)
- The University of Melbourne (AU)
- Vanderbilt University (US)
- University of Michigan (US)
- University Hospital of Zurich (CH)
- Corbus Pharmaceuticals (United States) (US)
- Vanderbilt Health (US)
- University College London (GB)
- Nippon Medical School (JP)
Publication Details
- Journal
- ACR Open Rheumatology
- Published
- 2025-03-01
- DOI
- https://doi.org/10.1002/acr2.70004
- Citations
- 6
- Primary Topic
- Systemic Sclerosis and Related Diseases
- Type
- article
- Field-Weighted Citation Impact
- 8.83